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Pharmaceutics
compliance and flexibility in formulation. Extended release 
oral drug formulations have been used since 1960s to 
enhance performance and increase patient compliance.[1] 
By incorporating the dose for 24 h into one tablet from 
which the drug is slowly released, peaks of high plasma 
concentration and troughs of low plasma concentration can 
be prevented.[2] This helps to avoid the side effects associated 
with high concentrations and the lack of activity associated 
with low concentrations, giving better overall therapy. In 
biopharmaceutics, scientists generally are faced with an 
engineering problem: To develop drug delivery systems 
that hit a desired target. The target in pharmacokinetics 
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ABSTRACT
The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin 
using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct 
compression method. Results of the preliminary trials indicated that the polymers used have significant 
release retarding effect on the formulation. To study the effect of concentration of polymers on drug release 
from matrix tablets, 32 full factorial design was applied. The concentration of HPMC K15M and HPMC 15cps 
were used as independent variables, while percentage drug release was selected as dependent variable. The 
dissolution data were fitted into zero‑order, first‑order, Higuchi and Korsemeyer–Peppas models to identify 
the pharmacokinetics and mechanism of drug release. Comparative study of dissolution profile of final batch 
F3 with market preparation (Sporidex AF 375) was done by similarity factor (f2) determination and it was 
concluded that final formulation F3 (10% HPMC K15M, 17.5% HPMC 15cps) shows good similarity with the 
market product. The results of the accelerated stability study of final formulation F3 for 1 month revealed that 
storage conditions were not found to have made any significant changes in final formulation F3. The release 
of cephalexin was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet 
was formulated. 
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is generally a plasma/blood drug concentration that lies 
between the minimum effect concentration (MEC) and 
minimum toxic concentration (MTC). Cephalexin is a 
semisynthetic antibiotic derived from cephalosporin C and is 
almost completely absorbed from the gastrointestinal tract, 
with a bioavailability of 95%. Cephalexin has a half‑life of 
around 1.1 h.[3‑5] To maintain therapeutic range, the drug 
should be administered 3–4 times a day, which leads to 
sawtooth kinetics and resulting in ineffective therapy.[6] 
Addressing this problem, we attempted to formulate 
extended release tablets of cephalexin, which can provide 
constant effective drug level for 6 h, based on calculations 
considering pharmacokinetic parameters. 
MATERIALS AND METHODS
Materials
The chemicals used in the experiment were: Cephalexin 
monohydrate (Aurobindo Pharma Ltd., Hyderabad, 
India), microcrystalline cellulose PH102 (Weiming 
Industries, China), lactose anhydrous (DMV‑Fonterra 
Excipients, Germany), hydroxypropyl methyl cellulose 
(HPMC) 15cps and HPMC K15M (Feicheng Ruitai Fine 
chemicals, China), colloidal silicon dioxide (Degussa India 
Pvt. Ltd., Mumbai, India), magnesium stearate (Ferro 
Corporation, USA), Sporidex AF 375 (Ranbaxy laboratories 
Pvt. Ltd., Gurgaon, India). All the other reagents used were 
of analytical grade.
Methods
Preparation and evaluation of  cephalexin monohydrate granules[7]
Accurately weighed quantities of drug and excipients were 
passed through sieve no: 20 and 40, respectively. Drug and 
excipients (excluding lubricant) were added in geometric 
proportions and mixed thoroughly for 15 min. The blend 
was mixed finally with lubricant to get the granules of 
cephalexin monohydrate. The flow properties of granules 
were characterized in terms of angle of repose, Carr’s 
index and Hausner’s ratio. The bulk density and tapped 
density were determined using USP bulk density apparatus 
(Veego Industries, Mumbai, India). The data summarized 
in Table 1.
Formulation of  cephalexin matrix tablets using direct compression 
method[8]
The prepared granules of cephalexin monohydrate 
were compressed in 15 × 8.5 mm punches of 27 station 
rotary tablet compression machine (CMB4D Cadmach, 
Ahmadabad, India). The formulae for batches F1–F9 are 
shown in Tables 2 and 3.
Evaluation of  tablet properties[8,9]
The prepared cephalexin matrix tablets were evaluated for 
thickness, hardness, friability, uniformity of weight and 
drug content. The thicknesses of tablets were measured 
using vernier caliper (Aerospace, China). Hardness of 
tablets was tested using a validated modified dial type 
hardness tester (Shivani Scientific Industries, Mumbai, 
India). Friability of tablets was determined by using 
Roche Friabilator (Electrolabs, Banglore, India). The drug 
content of each batch was determined as per USP assay of 
cephalexin using high performance liquid chromatography 
(HPLC; SCL‑10AVP, Shimadzu Corporation, Japan).[10] The 
results are shown in Table 4.
In vitro drug release study
The drug release studies of cephalexin matrix tablets were 
performed using dissolution testing apparatus USP type I 
(Basket type; Electrolabs, Banglore, India). The dissolution 
Table 1: Pre‑compression parameters of final batches 
F1–F9












F1 32°21′ ± 0.57 0.58 ± 0.41 0.72 ± 0.18 19.22 ± 0.31 1.23 ± 0.43
F2 34°16′ ± 0.32 0.57 ± 0.54 0.68 ± 0.23 16.22 ± 0.58 1.19 ± 0.38
F3 33°35′ ± 0.64 0.56 ± 0.27 0.67 ± 0.45 16.14 ± 0.19 1.19 ± 0.87
F4 34°45′ ± 0.87 0.57 ± 0.36 0.70 ± 0.52 17.75 ± 0.72 1.21 ± 0.66
F5 32°31′ ± 0.49 0.58 ± 0.19 0.72 ± 0.31 19.97 ± 0.54 1.24 ± 0.33
F6 34°43′ ± 0.71 0.54 ± 0.32 0.65 ± 0.49 16.67 ± 0.27 1.20 ± 0.18
F7 35°17′ ± 0.36 0.56 ± 0.67 0.68 ± 0.48 18.10 ± 0.16 1.22 ± 0.25
F8 35°26′ ± 0.25 0.56 ± 0.22 0.68 ± 0.14 16.88 ± 0.23 1.20 ± 0.55
F9 34°43′ ± 0.68 0.55 ± 0.12 0.66 ± 0.65 16.19 ± 0.69 1.19 ± 0.79
*The values are expressed as Mean ± SD; n=3
Table 2: Composition of optimization batches F1–F5
Ingredients Quantity used (mg/tab)
F1 F2 F3 F4 F5
Cephalexin monohydrate 401.25 401.25 401.25 401.25 401.25
Microcrystalline cellulose 22.15 36.65 7.65 33.75 48.25
HPMC K15M 58.00 58.00 58.00 46.40 46.40
HPMC K15cps 87.00 72.50 101.50 87.00 72.50
Colloidal silicon dioxide 5.80 5.80 5.80 5.80 5.80
Magnesium stearate 5.80 5.80 5.80 5.80 5.80
Average tablet weight 580.00 580.00 580.00 580.00 580.00
Table 3: Composition of optimization batches F6–F9
Ingredients Quantity used (mg/tab)
F6 F7 F8 F9
Cephalexin monohydrate 401.25 401.25 401.25 401.25
Microcrystalline cellulose 19.25 45.35 59.85 30.85
HPMC K15M 46.40 34.80 34.80 34.80
HPMC K15cps 101.50 87.00 72.50 101.50
Colloidal silicon dioxide 5.80 5.80 5.80 5.80
Magnesium stearate 5.80 5.80 5.80 5.80
Average tablet weight 580.00 580.00 580.00 580.00Jishnu, et al.: Formulation and evaluation of cephalexin extended release tablet
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testing was performed using 900 ml of 0.01 N HCl for the 1st h 
and phosphate buffer, pH 6.8, from 2nd h to 6th h at 37 ± 0.5°C 
temperature and speed 100 rpm for 6 h. A sample (5 ml) 
of the solution was withdrawn from the dissolution testing 
apparatus at 1st, 2nd, 4th and 6th h and the samples were replaced 
with fresh dissolution medium. The samples were filtered 
through a 0.45 μm membrane filter and diluted to a suitable 
concentration with the corresponding medium. Absorbance 
of these solutions was measured at 262 nm using UV‑1650 
spectrophotometer (Shimadzu Corporation, Japan).[11] The 
in vitro drug release specification was 20–40% at 1st h, 40–60% 
at 2nd h, 60–80% at 4th h and >80% at 6th h, determined 
from theoretical drug release and dissolution pattern of the 
marketed product. The in vitro drug release data is a singular 
term which shows a single set of grouped data shown in 
Table 5 and also graphically represented in Figures 1 and 2.
Experimental design[12,13]
A 32 full factorial design was adopted and the amount 
of polymers, HPMC K15M (X1) and HPMC K15cps 
(X2), were taken as independent variables and cumulative 
percentage drug release at 1st h (Y1), 2nd h (Y2) and 4th h (Y3) 
was taken as dependent variables as shown in Table 6. The 
factors were studied at three levels (−1, 0, +1) indicating 














F1 1.32 ± 1.34 5.46 ± 0.05 10.26 ± 1.11 97.19 0.03 ± 0.35
F2 2.37 ± 2.16 5.54 ± 0.06 12.59 ± 2.20 95.66 0.04 ± 0.51
F3 2.13 ± 1.48 5.52 ± 0.04 11.23 ± 1.25 96.12 0.03 ± 0.82
F4 2.74 ± 2.79 5.43 ± 0.08 11.46 ± 1.74 96.64 0.04 ± 0.53
F5 1.55 ± 3.13 5.57 ± 0.07 10.28 ± 2.28 97.23 0.02 ± 0.67
F6 2.31 ± 2.42 5.43 ± 0.05 12.22 ± 2.35 95.16 0.06 ± 0.18
F7 1.12 ± 3.19 5.56 ± 0.06 10.61 ± 1.76 94.89 0.03 ± 0.52
F8 2.07 ± 3.67 5.54 ± 0.04 11.55 ± 2.22 98.48 0.05 ± 0.76
F9 2.72 ± 2.43 5.45 ± 0.02 10.57 ± 2.36 96.53 0.02 ± 0.84
*Values are expressed as mean ± SD; n=20. **Values are expressed as mean ± SD; n=3





Cumulative percentage drug release (%)*
1st h 2nd h 4th h 6th h
F1 39.31 ± 0.73 57.48 ± 0.99 68.16 ± 0.99 93.07 ± 1.10
F2 45.96 ± 0.72 59.99 ± 1.02 70.82 ± 0.99 94.74 ± 1.29
F3 30.18 ± 1.12 49.74 ± 1.54 70.24 ± 1.50 94.38 ± 0.76
F4 42.51 ± 0.73 61.47 ± 1.30 76.33 ± 0.73 98.00 ± 1.24
F5 46.64 ± 0.62 64.36 ± 0.89 76.09 ± 0.80 96.48 ± 1.08
F6 33.64 ± 0.89 55.22 ± 0.74 73.21 ± 0.90 97.34 ± 0.80
F7 43.96 ± 1.02 64.34 ± 1.69 82.41 ± 1.01 97.12 ± 0.92
F8 48.68 ± 0.65 68.49 ± 0.78 84.39 ± 1.15 98.45 ± 0.59
























F1 0.0 0.0 42.51 61.47 76.33
F2 0.0 1.0 33.64 55.22 73.21
F3 1.0 1.0 30.18 49.74 70.24
F4 1.0 0.0 39.31 57.48 68.16
F5 −1.0 1.0 35.13 58.76 81.85
F6 1.0 −1.0 45.96 59.99 70.82
F7 −1.0 0.0 43.96 64.34 82.41
F8 0.0 −1.0 46.64 64.36 76.09
F9 −1.0 −1.0 48.68 68.49 84.39
Table 7: Correlation of actual and coded factors
Factor level Coded 
form









Low −1 34.80 72.50 6.00 12.50
Medium 0 46.40 87.00 8.00 15.00
High +1 58.00 101.50 10.00 17.50
low, medium and high, respectively, as represented in 
Table 7. The statistical optimization procedure was 
performed with the help of optimization softwares like 
Design Expert 8 (Stat‑Ease Inc., Minneapolis, MN, USA) Jishnu, et al.: Formulation and evaluation of cephalexin extended release tablet
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and Statgraphics Centurion XVI (StatPoint Technologies, 
Inc. Warrenton, Virginia, USA). The software performs the 
multiple regression analysis (MRA), analysis of variance 
(ANOVA) and statistical optimization.
Multiple regression analysis[12]
The use of regression analysis in 32 factorial design 
generates polynomial equations for different models, 
with interacting terms and regression coefficients, useful 
in evaluating the responses. The software generates two 
models, particularly, full model (non‑significant terms 
included) and reduced model (excluding non‑significant 
terms). In the full model study, the responses were analyzed 
using the quadratic equation below:
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X1
2 + b22X2
2 
where Y is the response evaluated, b0 is the arithmetic 
mean response of 9 runs and bi is the estimated coefficient 
of Xi. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high 
value. The interaction term (X1 X2) shows how the response 
changes when two factors are simultaneously changed. The 
polynomial terms (X1
2 and X2
2) were included to investigate 
nonlinearity.
In the reduced model study, the non‑significant terms 
in the quadratic equation are removed using backward 
regression procedure to generate a reduced model which 
is more important in studying the influence of factors on 
the responses evaluated. The value and sign of regression 
coefficient (bi) indicates the magnitude of influence of the 
particular term on the response. The regression coefficients 
give the average change in a response when the particular 
factor is changed by a unit, when all the other terms remain 
constant. A positive sign on the regression coefficient 
indicates the factor has a positive effect on the response 
and negative sign indicates a negative effect.
ANOVA study[13]
The software performs the individual analysis of responses 
and calculates the sum of squares (SS), mean square (MS), 
Fischer’s ratio (F statistics) and P value. The F statistics and 
P value give the significance level of each term, considering 
the null hypothesis (H0) is true. The terms with a P value less 
than 0.05 are considered significant at a level of significance 
α = 0.05. When the F value obtained is greater than the 
critical F value from the F distribution table, the factor 
becomes significant and the null hypothesis is rejected.
Comparison of  dissolution profiles[14]
The similarity in drug release pattern of the marketed 
product (Sporidex AF 375) and the formulation developed 
was compared by similarity factor (f2) determination. The 
two products are said to be similar if the value of f2 lies 
between 50 and 100. The similarity factor and a similarity 
testing have been recommended for dissolution profile 
comparison in the Food and Drug Administration (FDA)’s 
Guidance for Industry. The f2 is calculated using the 
formula given below:





where Rt is the percentage of reference product dissolved at a 
specified time, Tt is the percentage of test product dissolved 
at a specified time, and n is the number of sampling points.
Pharmacokinetic study[14,15]
To study the release kinetics, the data obtained from in vitro 
drug release studies were plotted in various kinetic models 
as follows:
1.  Zero order: Cumulative % of drug released versus time 
(Qt = Q0 − K0t);
2.  First order: Log cumulative % of drug remaining versus 
time (ln Q = ln Q0 − K1t);
3.  Higuchi: Cumulative % of drug released versus square 
root of time (Q = Kt1/2); and
4.  Korsmeyer–Peppas: Log cumulative % of drug released 
versus log time (Mt/Mα = Ktn),
where Qi and Ki stand for the amount of drug release and 
kinetic release constant, respectively. Mt/Mα indicates the 
fractional drug release and “n” is the diffusional exponent 
which gives the mechanism of drug release. When n<0.5, 
the drug diffuses through the polymeric matrix by a 
Fickian (case I) diffusion mechanism. For 0.5 < n<1, an 
anomalous (non‑Fickian) mechanism occurs; n=1 indicates 
a zero‑order (case II) and n>1 indicates non‑Fickian super 
case II release mechanism.
The plots were drawn using Microsoft excel 2007 and the 
regression equations were obtained for each plot. The linearity 
of the plots was obtained from the value of regression 
coefficient (R). The model with the highest linearity (R value 
approaching unity) was chosen as the best fit kinetic model.
Accelerated stability studies[16]
Short‑term accelerated stability studies were performed 
on the optimized tablet formulations of blister packed 
cephalexin extended release tablets. The tablets were 
subjected to stability studies at 40°C/75% relative humidity 
(RH) in a stability chamber (Servewell Instrument Pvt. Ltd., 
Bengaluru, India) for a period of 1 month. Initial evaluation Jishnu, et al.: Formulation and evaluation of cephalexin extended release tablet
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of the tablets was done, and at the end of first month the 
tablets were again analyzed for their physical appearance, 
water content and in vitro drug release profile.
RESULTS AND DISCUSSION
The bulk density of granules was found to be between 
0.54 ± 0.32 and 0.58 ± 0.41 g/cm3. This indicates good 
packing capacity of granules. Carr’s index was found to be 
between 16.14 ± 0.19 and 19.97 ± 0.54, showing good flow 
characteristics. Hausner’s ratio ranged from 1.19 ± 0.38 to 
1.24 ± 0.33, which indicates good flowability. The angle 
of repose of all the formulations was within the range 
of 32°21′ ± 0.57 to 35°26′ ± 0.25, i.e. the granules of 
cephalexin have fair flow properties.
The thickness ranged from 5.43 ± 0.08 mm to 5.57 ± 0.07 mm, 
and the hardness ranged from 10.26 ± 1.11 kg/cm2 to 
12.59 ± 2.20 kg/cm2. The friability ranged from 0.02 ± 0.67 
to 0.06 ± 0.18. The values of percentage weight variation 
ranged from 1.12 ± 3.19 to 2.74 ± 2.79. Drug content ranged 
from 98.48 ± 0.12% w/w to 94.89 ± 0.13% w/w, indicating 
good content uniformity among the prepared formulations.
Multiple regression analysis
Backward regression analysis technique was used to 
generate the best fit models for the analyzed responses. 
The equations were obtained both for coded and actual 
values of factors. The final equation of reduced model 
contains only the significant factor terms corresponding 
to the response analyzed. 
Reduced model equation for responses in terms of actual 
factors:
1.  Release at 1st h (Y1) = 24.49 − 0.18 HPMC K15M + 1.08 
HPMC 15cps – 0.009 HPMC 15cps2
2.  Release at 2nd h (Y2) = 46.35 − 0.35 HPMC 
K15M + 1.047 HPMC 15cps2 – 0.008 HPMC 15cps2
3.  Release at 4th h (Y3) = 102.2 − 0.5665 HPMC K15M
Reduced model equation for responses in terms of coded 
factors:
1.  Release at 1st h (Y1) = 41.93 – 2.05 X1 – 7.05 X2 – 1.89 
X2
2
2.  Release at 2nd h (Y2) = 61.10 – 4.06 X1– 4.85 X2 – 1.67 
X2
2
3.  Release at 4th h (Y3) = 75.94 – 6.57 X1
The inferences from reduced model analysis are: The 
release at 1st and 2nd h is influenced by both the polymers. 
The reduced model equation in actual factors indicates that 
HPMC K15M decreases the drug release from the tablet 
during 1st, 2nd and 4th h as the coefficients carry a negative 
sign. It also indicates that the HPMC 15cps increases the 
drug release from the tablet during 1st and 2nd h as the 
coefficients carry a positive sign and the polymer has no 
effect at the 4th h as it is a non‑significant term.
ANOVA (Analysis of variance) studies
The ANOVA of 1st h from Table 8 indicates that both 
HPMC K15M and HPMC 15cps are significant terms as 
the F values are above the critical F values, thus making 
the P values less than 0.05 (threshold level). Thus, the null 
hypothesis H0 is rejected and the alternate hypothesis that 
the two polymers used significantly influence the rate of drug 
release from the cephalexin matrix tablets is found to be true.
The ANOVA of 2nd h from Table 9 shows that both HPMC 
K15M and HPMC 15cps are significant terms, indicating 
that both the polymers influence the rate of drug release 
at the 2nd h from the cephalexin matrix tablets and the 
alternate hypothesis holds good in this case.
The ANOVA of 4th h from Table 10 indicates that the 
only term significant is HPMC K15M, and HPMC 15cps 
was found to have no influence in the 4th h release from 
cephalexin matrix tablets. The polymer HPMC 15cps 
with a low viscosity is found to have rate‑controlling 
effect only in the initial hours and HPMC K15M with a 
higher viscosity grade has rate‑controlling effects even 
in the 4th h.
The 3D response surface plots give a representation of 
Table 8: Analysis of variance for 1st h
Source Sum of squares DF Mean square F ratio P value
A: K15M 25.2971 1 25.2971 55.09 0.0051*
B: 15CPS 298.638 1 298.638 650.40 0.0001*
AA 0.309422 1 0.309422 0.67 0.4719
AB 1.24323 1 1.24323 2.71 0.1984
BB 7.13161 1 7.13161 15.53 0.0291*




Source Sum of squares DF Mean square F ratio P value
A: K15M 99.0641 1 99.0641 205.77 0.0007*
B: 15CPS 141.329 1 141.329 293.57 0.0004*
AA 0.605 1 0.605 1.26 0.3439
AB 0.0676 1 0.0676 0.14 0.7328
BB 5.5778 1 5.5778 11.59 0.0423*
Total error 1.44427 3 0.481422
Total (corr.) 248.088 8
*Significant values. “DF” stands for degree of freedomJishnu, et al.: Formulation and evaluation of cephalexin extended release tablet
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the variations in each response when the two factors are 
simultaneously changed from lower level to higher level. 
They also give a three‑dimensional curvature of the change 
in response at different factor levels and also give the 
variation in design points from the predicted response value. 
The response plots are shown in Figures 3–5.
Pharmacokinetic report
The kinetic summary from Table 11 reveals that 
cephalexin extended release tablets follow zero‑order 
kinetics as the regression coefficients approach unity, 
indicating that the drug release is independent of drug 
concentration. The n values from Korsemeyer–Peppas 
model show that the drug release pattern follows mainly 
Fickian diffusion mechanism, but erosion too plays a 
significant role as the formulations F3, F6, F9 show 
n values above 0.5. The Higuchi plots also show good 
linearity, indicating that the drug release is proportional 
to the square root of time and the drug release is at a 
slower rate as the distance of diffusion increases.
Comparison of dissolution profiles
The similarity factor (f2) shown in Table 12 indicates that 
F3 gave the most similar dissolution profile to that of 
the marketed product. Thus, F3 was determined as the 
optimized product and is preferred for scale‑up batches. 
The drug release pattern of optimized product F3 and 
theoretical release pattern were compared to determine the 
similarity and is shown in Figure 6. The graph shows good 
Table 10: Analysis of variance for 4th h
Source Sum of squares DF Mean square F ratio P value
A: K15M 259.121 1 259.121 127.28 0.0015*
B: 15CPS 6.0 1 6.0 2.95 0.1845
AA 2.42734 1 2.42734 1.19 0.3547
AB 0.9604 1 0.9604 0.47 0.5415
BB 0.435556 1 0.435556 0.21 0.6752
Total error 6.10751 3 2.03584
Total (corr.) 275.052 8
*Significant values “DF” stands for degree of freedom
Figure 3: 3D plot for percentage drug release at the 1st h
Table 11: Kinetics modeling summary
Code Kinetic model
Zero order First order Korsemeyer Higuchi
R2 K0 R2 K1 R2 n R2 KH
F1 0.964 9.950 0.844 0.679 0.967 0.45 0.960 34.48
F2 0.970 15.71 0.876 0.439 0.963 0.38 0.958 31.58
F3 0.997 21.31 0.924 0.483 0.994 0.62 0.993 43.00
F4 0.976 10.45 0.877 0.635 0.986 0.45 0.984 36.48
F5 0.969 9.288 0.894 0.513 0.979 0.38 0.976 32.37
F6 0.997 20.90 0.889 0.612 0.987 0.57 0.988 42.09
F7 0.994 17.75 0.95 0.573 0.989 0.43 0.989 35.80
F8 0.993 16.52 0.924 0.67 0.988 0.38 0.985 33.27
F9 0.993 21.27 0.995 0.469 0.985 0.57 0.990 42.95
R2 = regression coefficient, K0 = zero‑order release rate constant, K1 = first‑order 
release rate constant, n=diffusional exponent, KH = Higuchi rate constant
Figure 4: 3D plot for percentage drug release at the 2nd h
correlation between the dissolution profiles of marketed 
product F3 and the theoretical release pattern.
Accelerated stability study report
The accelerated stability study report shown in Table 13 
reveals that the formulation has not undergone any physical 
or chemical degradation during the period. There are no 
significant differences in the in vitro drug release and the 
drug content of the optimized formulation.Jishnu, et al.: Formulation and evaluation of cephalexin extended release tablet
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CONCLUSIONS
The major conclusions from the study are:
1.  Improvement in the efficacy of cephalexin oral therapy 
was achieved by formulation of cephalexin extended 
release matrix tablets, as the frequency of dosing was 
decreased, thus improving patient compliance. 
2.  The sawtooth kinetics of conventional therapy was 
completely avoided by the development of new formulation.
3.  The in vitro drug release profile of the newly developed 
tablets also shows good similarity with that of the   
innnovator product and ideal controlled release pattern.
4.  There were no formulation problems associated with 
the optimized batch of cephalexin matrix tablets.
5.  The tablet also passed the short‑term accelerated 
stability studies, indicating the physical and chemical 
stability of the product.
Future prospects of the study
The marketing of the product is possible only after 
bioequivalence studies with innovator’s product. Particle size 
analysis of cephalexin monohydrate and pilot‑scale studies 
of the formulation also need to be performed. Long‑term 
stability studies as per ICH guidelines are also proposed. 
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